| HOME >> BIOLOGY >> TECHNOLOGY |
11,29933,237Operating costs and expenses: Cost of goods sold
3,2634,296 Research and development
30,17623,286 General and administrative
11,7279,013Total operating costs and expenses
45,16636,595Loss from operations
(33,867)(3,358)Non-operating income (expense):Interest income
432463Interest expense
(2,585)(2,951)Other income, net
13424Total non-operating expense
(2,019)(2,464)Loss before provision for income taxes
(35,886)(5,822)Provision for income taxes
148308Net loss
$ (36,034)$ (6,130)Basic and diluted net loss per share
$
(0.33)$ (0.07)Weighted average shares used in computing basic and diluted net loss per share
108,67793,631NEKTAR THERAPEUTICSCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(In thousands)(unaudited)Three Months Ended March 31,20112010Cash flows from operating activities:Net loss
$ (36,034)$ (6,130)Adjustments to reconcile net loss to net cash used in operating activities:Depreciation and amortization
3,8564,149Stock-based compensation
4,8023,744Other non-cash transactions
309(235)Changes in operating assets and liabilities:Accounts receivable
22,942(2,908)Inventory
(4,446)(2,232)Other assets
(1,199)(883)Accounts payable
(2,895)1,748Accrued compensation
(1,572)(4,348)Accrued expenses
1,9611,354Accrued clinical trial expenses
1,505(552)Deferred revenue
(2,555)(26,568)Other liabilities
(1,544)(1,302)Net cash used in operating activities
$ (14,870)$ (34,163)Cash flows from investing activities:Purchases of investments
(372,723)(115,277)Maturities of investments
113,235112,074Sales of investments
61,3688,197Purchases of property and equipment
(3,765)(3,973)Net cash (used in) provided by investing activities
$ (201,885)$
,021Cash flows from financ
'/>"/>
| SOURCE Nektar Therapeutics Copyright©2010 PR Newswire. All rights reserved |